Avammune Therapeutics's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Avammune Therapeutics: the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Avammune Therapeutics funding history
No funding rounds for Avammune Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Avammune Therapeutics valuation
Avammune Therapeutics's last reported valuation was $33 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
How Avammune Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Avammune Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →
Frequently asked about Avammune Therapeutics
- What is Avammune Therapeutics worth?
- Avammune Therapeutics is valued at $33.0M as of Oct 2026. Avammune Therapeutics's last reported valuation, May 2025. Nothing priced has surfaced since.
- How much has Avammune Therapeutics raised?
- Avammune Therapeutics has raised $18.5M in total funding across its recorded rounds.